Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah B Berman

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic MyelopathyJohn V Pluvinage, David Acero-Garces, Giacomo Greco, et al.
Nature Neuroscience|July 10, 2023
Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)Nicole S McKay, Brian A Gordon, Russ C Hornbeck, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stageNelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic MyelopathyJohn V Pluvinage, David Acero-Garces, Giacomo Greco, et al.
Nature Neuroscience|July 10, 2023
Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)Nicole S McKay, Brian A Gordon, Russ C Hornbeck, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stageNelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Pageof 8